GLP-1 adoption strains employer health plans and restructures pharmacy benefit manager rebates

Supply Bottlenecks and Cost Burdens Dictate the $200B Incretin Market

The glucagon-like peptide-1 receptor agonist market is projected to reach $200 billion by 2030. Incretin therapies are expanding beyond basic glycemic control to broad cardiometabolic risk reduction. This utilization alters employer health plan economics and forces structural shifts across pharmaceutical value chains. A massive demand shock is colliding with physical manufacturing constraints and a fragmenting rebate intermediary system. As millions of patients seek access to these therapies, the resulting strain on healthcare budgets and supply chains dictates how pharmaceutical capital is deployed and how payers absorb costs.

A concentrated duopoly controls this market. The two dominant companies face distinct structural constraints and pursue divergent capital allocation strategies. Eli Lilly generated approximately $65.2 billion in 2025 revenue, with its tirzepatide franchise accounting for 56% of total corporate sales. The company targets absolute volume scale through capital expenditures, committing over $50 billion toward domestic manufacturing infrastructure and increasing its 2025 capital expenditures by 55.0% to $7.8 billion. Novo Nordisk derived $34.6 billion of its $46.8 billion total revenue from its semaglutide portfolio and relies on acquisitive capacity integration to manage supply bottlenecks. These approaches expose the physical limitations of sterile injectable manufacturing, a constraint that dictates market share over clinical efficacy.